SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?


To: Bluegreen who wrote (8414)1/22/1999 2:06:00 AM
From: aknahow  Read Replies (1) | Respond to of 17367
 
339 meningo patients (1/19/99); 584 trauma (1/14/99)
Trigger: Ellen Martin
Gun: XOMA
When: 3 p.m. and now.
Where: Berkley.

BTW I am having trouble with the post on total deaths. Just do not make any sense. <g>

Bluegree, glad your back and redeeming yourself with that splendid info., almost a book on the Host Defense Mechanism. Wonder where Robert_K was and why he never comes up with anything new!



To: Bluegreen who wrote (8414)1/22/1999 11:26:00 AM
From: aknahow  Read Replies (1) | Respond to of 17367
 
Bluegreen, any link to seasonality of trauma cases? I would think, various forms of trauma decline during the winter, stabbings', gunshots and etc but that other types might increase due to more serious multiple traffic accidents. Think it would be possible even for me to incorporate such a factor into my graph.

Wonder if Robert_K has read the book, on host defense that you discovered, and what he thinks about this information?



To: Bluegreen who wrote (8414)1/22/1999 11:35:00 AM
From: aknahow  Respond to of 17367
 
Monsanto said this about sweeteners:

" Monsanto's Neotame announcement was a low-key, one-sentence mention in the
company's report on 1998 financial results. "We didn't want to raise
expectations because it takes a fair amount of time to get sweeteners
approved," said Lori Fisher, a Monsanto spokeswoman."

I thought Thaumatin a XOMA sweetener already had approval? I still think of this as a sleeper, that could bring in big bucks if they could ever get it licensed to a company that would really market it.